— Ace Therapeutics, a globally recognized preclinical contract research organization (CRO), reinforces its leadership in respiratory drug research by delivering tailored and reliable preclinical respiratory CRO services to pharmaceutical enterprises, academic institutions, and research groups across the world, aiming to streamline the entire preclinical development journey for novel respiratory therapeutics.
Respiratory disorders including asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and refractory cough continue to pose substantial unmet medical needs globally, driving rising demand for rigorous preclinical research to validate candidate drugs before clinical translation.
As a dedicated preclinical research partner, Ace Therapeutics has built a full-spectrum service portfolio centered on respiratory disease research, with in vivo respiratory disease models standing as one of its core technical strengths. Ace Therapeutics has established a diverse panel of well-validated animal models covering multiple species such as mice, rats, guinea pigs, and rabbits, which accurately recapitulate the pathological features, inflammatory mechanisms, and physiological responses of human respiratory conditions. These models support in-depth mechanistic exploration, efficacy evaluation, and safety assessment for therapies targeting airway inflammation, cough reflex, lung tissue remodeling, and other key pathways, generating highly translational data for clients’ research projects.
Beyond the development of in vivo respiratory disease models, Ace Therapeutics provides integrated solutions including in vitro compound screening, inhalation delivery system optimization, pharmacokinetic analysis, efficacy testing, and comprehensive biomarker analysis. Supported by state-of-the-art laboratory facilities and a team of seasoned scientists with extensive experience in respiratory research, Ace Therapeutics customizes study protocols based on clients’ unique research objectives, whether for early target validation, lead compound screening, or large-scale preclinical proof-of-concept studies. All research activities adhere to international quality and ethical standards, ensuring the reproducibility and credibility of experimental results.
For researchers and drug developers focusing on respiratory treatments, selecting appropriate animal models and professional CRO support are critical to shortening R&D cycles and lowering project risks. Ace Therapeutics’ flexible service mode enables seamless collaboration with clients at every research stage. From designing customized in vivo respiratory disease models for specific disease phenotypes to executing end-to-end preclinical testing, Ace Therapeutics strives to remove technical barriers and accelerate the progression of promising respiratory drug candidates toward clinical trials.
With a growing footprint across North America and Europe, Ace Therapeutics continues to upgrade its technical platforms and expand its model library for respiratory diseases. It remains committed to advancing preclinical respiratory research, and will keep optimizing its service system to support more breakthroughs in the field of respiratory therapeutics in the long run.
About Ace Therapeutics
Ace Therapeutics is a professional preclinical CRO focusing on one-stop preclinical research services. Its service scope spans efficacy assessment, toxicology research, pharmacokinetic analysis, model development, and biomarker research across multiple therapeutic areas. Rooted in rigorous scientific standards and innovative technologies, Ace Therapeutics serves global clients from biotech firms and large pharmaceutical companies to academic research labs, dedicating to driving the efficient development of new drugs and novel therapies.
Contact Info:
Name: Daisy Mostert
Email: Send Email
Organization: Ace Therapeutics
Website: https://www.acetherapeutics.com/
Release ID: 89197646
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.